News & Events
- Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference
- Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out
- Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
- Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660
- Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020
- Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer
- Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates
- Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
- Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit
- Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation
- Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights
- Seres Therapeutics to Present at the Cowen 2020 Health Care Conference
- Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020
- Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
- Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors